title: Formulation study of oxybutynin patches.
abstract: The present feasibility study was designed to obtain a monolayer patch containing oxybutynin (OXY) avoiding chemical permeation enhancers. The highest flux was obtained with a polydimethylsiloxane matrix patch. Because OXY crystals were detected in the matrix within a week, two amino methylmethacrylate copolymers (Eudragit E or Eudragit RS) were used as OXY crystallization inhibitors. A preliminary in vivo study indicated that flux from the stabilized patches had to be increased about 30-40%. This goal was reached by occlusion with a polyethylene layer.
authors.affiliation: Istituto di Chimica Farmaceutica e Tossicologica Pietro Pratesi, University of Milan, Milano, Italy. paola.minghetti@unimi.it
authors.forename: Paola
authors.initials: P
authors.lastname: Minghetti
authors.forename: Francesco
authors.initials: F
authors.lastname: Cilurzo
authors.forename: Stefania
authors.initials: S
authors.lastname: Pagani
authors.forename: Antonella
authors.initials: A
authors.lastname: Casiraghi
authors.forename: Riccardo
authors.initials: R
authors.lastname: Assandri
authors.forename: Luisa
authors.initials: L
authors.lastname: Montanari
mesh_terms: D002152:Calorimetry, Differential Scanning; D004339:Drug Compounding; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008333:Mandelic Acids / Q000032:analysis / Q000493:pharmacokinetics* / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000032:analysis / Q000493:pharmacokinetics* / Q000494:pharmacology; D010539:Permeability / Q000187:drug effects; D012867:Skin / Q000187:drug effects; D017550:Spectroscopy, Fourier Transform Infrared
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin